Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 19, 2026, 3:17 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–8 of 8 matching trials from the live ClinicalTrials.gov search.
Conditions
Diabetic Macular Edema, DME, Diabetic Macular Edema (DME)
Interventions
EYP-1901, Aflibercept (2.0 mg)
Drug
Lead sponsor
EyePoint Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
53
States / cities
Bakersfield, California • Encino, California • Glendale, California + 49 more
Conditions
Diabetic Macular Edema
Interventions
EYP-1901, Aflibercept 2Mg/0.05Ml Inj,Oph
Drug
Lead sponsor
EyePoint Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
6
States / cities
Phoenix, Arizona • Lemont, Illinois • Hagerstown, Maryland + 3 more
Conditions
Wet Age Related Macular Degeneration, wAMD
Interventions
EYP-1901, Aflibercept (2.0 mg)
Drug
Lead sponsor
EyePoint Pharmaceuticals, Inc.
Industry
Eligibility
50 Years and older
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
76
States / cities
Phoenix, Arizona • Springdale, Arkansas • Bakersfield, California + 70 more
Conditions
Wet Age Related Macular Degeneration, wAMD
Interventions
EYP-1901, Aflibercept (2.0 mg)
Drug
Lead sponsor
EyePoint Pharmaceuticals, Inc.
Industry
Eligibility
50 Years and older
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
78
States / cities
Gilbert, Arizona • Phoenix, Arizona • Scottsdale, Arizona + 69 more
Conditions
Wet Age-related Macular Degeneration
Interventions
EYP-1901, Aflibercept 2mg/0.05mL Inj,Oph
Drug
Lead sponsor
EyePoint Pharmaceuticals, Inc.
Industry
Eligibility
50 Years and older
Enrollment
161 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
67
States / cities
Phoenix, Arizona • Springdale, Arkansas • Beverly Hills, California + 64 more
Conditions
Wet Age-related Macular Degeneration
Interventions
EYP-1901
Drug
Lead sponsor
EyePoint Pharmaceuticals, Inc.
Industry
Eligibility
50 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
11
States / cities
Phoenix, Arizona • Beverly Hills, California • Mountain View, California + 8 more
Conditions
Nonproliferative Diabetic Retinopathy
Interventions
EYP-1901, Sham IVT
Drug · Other
Lead sponsor
EyePoint Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
77 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
36
States / cities
Phoenix, Arizona • Huntington Beach, California • Oxnard, California + 33 more
Conditions
Diabetic Macular Edema, DME, Diabetic Macular Edema (DME)
Interventions
EYP-1901, Aflibercept (2.0 mg)
Drug
Lead sponsor
EyePoint Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
51
States / cities
Gilbert, Arizona • Phoenix, Arizona • Scottsdale, Arizona + 44 more